1-3 of 3
Gregory J. Hogan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Mark Roschewski, David M. Kurtz, Jason Westin, Ryan C. Lynch, Charles Macaulay, Christian Kuffer, Gregory J. Hogan, Sandra Close, Jacob J. Chabon, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh, Andre Schultz
Journal: Blood
Blood (2022) 140 (Supplement 1): 785–786.
https://doi.org/10.1182/blood-2022-167936
Published: 2022
Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2378–2380.
https://doi.org/10.1182/blood-2022-162150
Published: 2022
Journal Articles

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin
Journal: Blood
Blood (2022) 140 (Supplement 1): 3498–3499.
https://doi.org/10.1182/blood-2022-168378
Published: 2022